RECHERCHE

TARGETING PROTEINS IN ORDER TO BLOCK THE GROWTH OF TUMORS AND THE PROGRESSION OF LEUKEMIA FOR CHILDREN IN RELAPSE 

This trial was cofinanced by the 2016 Children without Cancer race.

A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory Cancers of childhood.

 

 

PARC (ITCC-062) is a phase-I trial on all cancers and leukemia for children in relapse. It aims to test the efficacy of a new treatment in order to block the growth of tumors and the progression of leukemia by targeting proteins. The BCT-100 is an arginase that metabolises arginine and prevents malignant cells from it. This trial allows to investigate tumoral metabolism inhibition for children.

Promotor: University of Birgmingham
Main investigator: Dr Francis Mussai
Program duration: 2018 – 2022 (2 years enrollment, 2 years patient follow-up)
Planned enrollment: August 2018 – August 2020
Objective of 64 patients (5 patients were included at the end of December 2018)
Countries involved: United Kingdom, Denmark, France, Germany, Ireland, Italy, Spain, the Netherlands, Australia, New Zealand 
Funding by Imagine for Margo: 130 000€
Other contributors: Cancer Research UK

 

Doctor Gudrun Schleiermacher speaks about the program:

X En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des contenus et services adaptés à vos centres d'intérêts. En savoir plus...Fermer